30-Mar-2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Mar 4:15 PM ET)
Business Wire (Tue, 3-Mar 7:00 AM ET)
Scholar Rock to Present at Upcoming Investor Conferences
Business Wire (Wed, 18-Feb 8:00 AM ET)
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Business Wire (Tue, 10-Feb 8:00 AM ET)
Scholar Rock Highlights 2026 Strategic Priorities
Business Wire (Mon, 12-Jan 7:00 AM ET)
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Mon, 5-Jan 8:00 AM ET)
Market Chameleon (Fri, 14-Nov 5:33 AM ET)
Scholar Rock Accelerates SMA Treatment Milestones While Strengthening Cash Position
Market Chameleon (Fri, 14-Nov 2:55 AM ET)
Market Chameleon (Tue, 23-Sep 3:52 AM ET)
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of March 30, 2026, SRRK stock price climbed to $43.08 with 727,910 million shares trading.
SRRK has a beta of 0.83, meaning it tends to be less sensitive to market movements. SRRK has a correlation of 0.04 to the broad based SPY ETF.
SRRK has a market cap of $4.39 billion. This is considered a Mid Cap stock.
Last quarter Scholar Rock Holding reported $0 in Revenue and -$.88 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, SRRK traded as high as $49.82 and as low as $5.56.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
SRRK has outperformed the market in the last year with a price return of +29.1% while the SPY ETF gained +12.7%. SRRK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -5.7% and +7.7%, respectively, while the SPY returned -8.2% and -4.3%, respectively.
SRRK support price is $40.89 and resistance is $44.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK shares will trade within this expected range on the day.